Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.39 USD | -3.80% | +2.17% | +41.83% |
03-19 | Morphic Holding Names Simon Cooper as Chief Medical Officer | MT |
03-15 | Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug | MT |
Evolution of the average Target Price on Keros Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Keros Therapeutics, Inc.
Wedbush | |
BofA Securities | |
Piper Sandler | |
Cowen | |
BTIG | |
Truist Securities |
EPS Revisions
- Stock Market
- Equities
- KROS Stock
- Consensus Keros Therapeutics, Inc.